Executive interview – RhoVac

Executive interview – RhoVac

Chosa — 1 video in collection

More on this equity

RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The ongoing Phase IIb study in prostate cancer is fully funded and results are expected around mid-2021. RhoVac’s strategic aim is to secure a partner for the late-stage development of RV001. In this video, Anders Månsson, RhoVac’s chief executive officer, introduces the company and its lead asset, RV001 and provides an overview of R&D progress and expected newsflow.


You may also be interested in these:

Healthcare

Cereno Scientific – executive interview

Healthcare

Sareum Holdings – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free